Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline.
